Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B

Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B

Background & Aims: A recent consensus document has defined metabolic dysfunction-associated fatty liver disease (MAFLD) as hepatic steatosis together with overweight, diabetes, and/or a combination of other metabolic risk factors. The clinical relevance of this novel diagnosis is unknown amo...

Full description

Bibliographic Details
Main Authors: Laurens A. van Kleef, Hannah S.J. Choi, Willem P. Brouwer, Bettina E. Hansen, Keyur Patel, Robert A. de Man, Harry L.A. Janssen, Robert J. de Knegt, Milan J. Sonneveld
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:JHEP Reports
Subjects:
Chronic hepatitis B
CHB
Hepatitis B
HBV
Metabolic dysfunction-associated fatty liver disease
MAFLD
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555921001269

Internet

http://www.sciencedirect.com/science/article/pii/S2589555921001269

Similar Items